1- Faculty of Nuclear Engineering and Physics, Amirkabir University of Technology, P.O. Box: 15875-4413, Tehran - Iran
2- Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-8486,Tehran– Iran
*email: R-adeli@aut.ac.ir
Abstract:
Pain palliation of bone metastases is one of the perspectives of medical science. Among the different modalities, the use of radionuclides is a well-established approach. One of these radionuclides is Yttrium-90 (90Y) associated with chemical component EDTMP. One method for production of 90Y, is neutron activation of 89Y. This radionuclide is a pure beta emitter with a high energy and appropriate half life and has been considered for medical usages in nuclear medicine. In this research 90Y has been produced by irradiation of Y2O3 powder and, by addition of EDTMP ligand, the 90Y-EDTMP complex has been achieved at ambient temperature. Radiochemical purity was investigated by ITLC method and radionuclidic purity by liquid scintillation counting. The radiopharmaceutical biodistributions were performed in different rat organs.
Keywords: Bone Metastases, Yttrium-90, EDTMP, Radiopharmaceutical, Biodistribution